Feedback / Questions
HT-4253 - Halia Therap
https://www.prnewswire.com/news-releases/halia-therapeutics-completes-first-in-human-phase-1-study-of-ht-4253-a-novel-lrrk2-inhibitor-targeting-neuroinflammation-302482102.html
Jun 16, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next